Overview
November 6: Short Course
November 9-10: Conference
Real World Evidence (RWE) is increasingly becoming important for regulatory decision-making and beginning to touch all areas of the healthcare value chain. Historically used for post-market safety monitoring, sponsors are now beginning to use RWE to support clinical trial design and observational studies in order to generate better treatment approaches, while healthcare systems are collecting and using RWE to substantiate coverage decisions.
DIA’s Real World Evidence Conference will explore new and innovative applications of RWE, and deliver cutting-edge insights in how stakeholders are leveraging RWE to advance healthcare knowledge and decision-making.
Preconference Short Course
Introduction to Real World Data for Data Geeks
Who should attend?
Professionals from industry, academia, and government involved in all phases of the medical product lifecycle including:
- Real World Evidence
- Epidemiology
- Policy
- Regulatory Science
- Technology development
- Data analytics
- Clinical Research
Learning objectives
- Explain how RWE is being used today to inform biopharmaceutic development across product lifecycle
- Describe the recent FDA strategic framework for RWD in regulatory decisions
- Evaluate the future applications of RWE in drug development
- Appraise how mobile technologies, AI, machine learning, and other technologies are being used to generate RWE
- Evaluate how patient reported outcomes, EHR, and other patient data is expanding the resources for RWE
- Discuss “lessons learned” from current uses of RWE, and how these can be applied for other future applications of RWE
Program Committee
-
Nancy A. Dreyer, PhD, MPH, FISPE •
IQVIA, United States -
Steven A. Anderson, PhD • Director, Office of Biostatistics and Epidemiology, CBER
FDA, United States -
Dorothee B. Bartels, PhD, MSc • Head of Global Real World Evidence and Digital Science
UCB Pharma, Belgium -
Brian D. Bradbury, PhD, MA • Vice President, Center for Observational Research
Amgen, United States -
Paul M. Coplan, DrSc, MBA, MSc, FISPE • Vice President, Medical Device Epidemiology & Real-World Data Analytics
Johnson & Johnson, United States -
Marni Hall, PhD, MPH • Vice President, Clinical Evidence
IQVIA, United States -
James Harnett, PharmD, MS • Executive Director, Health Economics & Outcomes Research
Regeneron Pharmaceuticals, Inc., United States -
Jingyu (Julia) Luan, PhD • Regulatory Affairs Director, BioPharmaceuticals R&D, Late-Stage Development, CRM
AstraZeneca, United States -
David Martin, MD, MPH • Vice President, Pharmacovigilance
Moderna, United States -
Robert Reynolds, DrSc, FISPE • Vice President, Epidemiology & Patient-Centered Outcomes
GlaxoSmithKline, United States -
Debra Schaumberg, DrSc, MPH • Vice President, Epidemiology & Head Strategic and Scientific Affairs
Evidera|Ppd, United States -
Mark Stewart, PhD • Vice President, Science Policy
Friends of Cancer Research, United States
Contact us
Registration Questions?
Preconference Short Course
Introduction to Real World Data for Data Geeks
On Demand Webinar
When Is Real World Evidence Ready for Prime Time Encore Presentation
Additional Information
DIA's Real World Evidence Resource Kit